Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Beckman Coulter Life Sciences Names Joe Fox President

October 1, 2024

Strengthening Healthcare IT Infrastructure: A Wake-Up Call for Cybersecurity Resilience

Jason Griffin, Managing Director, Digital Health Strategy and Cybersecurity at Nordic Consulting Andy Adams, Managing Director, Performance Improvement and Advisory Services at Nordic Consulting The recent

March 16, 2024

Burdock roots outshine dandelion in antidiabetic potential study

Study compares the antidiabetic potential of dandelion and burdock roots, finding burdock exhibits higher total phenolic content and α-amylase activity, while dandelion has higher total

April 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.